From, whom else, NIAID. This SBIR Phase II proposal, Identification of E. coli anti-infective rRNA targets, submitted on November 30, 2005 is exactly what reviewers read and scored (summary statement also available) except for the removal of some confidential information and intellectual property details. The applicants were the chief executive officer of RiboNovix, Alison Taunton-Rigby, Ph.D., and principal investigator, Cheryl Murphy, Ph.D. In my current position, I don’t support preparation of these types of applications, but for those of you in or partnering with small business, NIAID of course has many other excellent SBIR/STTR resources to help guide your submission.
